Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS (ocrelizumab). In the case of OCR,...
Read MoreLATE BREAKING
all categories
Brief Telehealth Screening of MS Patients in the Medical Setting
Background: A significant clinical need exists for a broad range of health care professionals to be able to objectively screen for the presence of MS-related...
Read More
Connect Trial of Online Professional Support Groups for Black and Latinx People Living with MS
Background: Given the high prevalence of anxiety and depression in MS, many patients struggle to find high quality, professional mental health services. Currently available options...
Read More
COVID-19 Vaccine Antigenicity in the Setting of MS Disease Modifying Treatments
Background: Although FDA-approved COVID vaccines prevent severe infections in the general population, their efficacy in the face of immune modulation or suppression is unclear. Vaccine...
Read More
Dimethyl Fumarate Is Associated with Lower Rates of Infection and Lower Infection-Related Healthcare Costs When Compared with Ocrelizumab
Background: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of hospitalization, and healthcare resource utilization (HRU). The...
Read More
Early Experience with Cladribine Tablets in an Aging Patient Population
Background: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade in persons with multiple sclerosis (MS) Cladribine tablets are...
Read More
Evaluating the Impact of Administering Ocrelizumab Via a Home Infusion on Safety and Patient Reported Outcomes
Background: US payers are looking to reduce the cost of administering infusible drugs for multiple sclerosis (MS). Home-based infusion has not been evaluated and may...
Read More
Geographic Variance of MS Prevalence in the United States
Background: The etiology of multiple sclerosis (MS) is not fully understood, and the disease may be triggered or exacerbated by environmental risk factors, some of...
Read More
Humoral and T-Cell Responses to Sars-Cov-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab
Background: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an anti-CD20 therapy. OCR has been shown...
Read More
Interim Results of Open-Label Multicenter Phase 4 Study Assessing Immune Response to Influenza Vaccine in Patients with Relapsing Multiple Sclerosis Treated with Ofatumumab
Background: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts humoral immune response to vaccines, including the influenza...
Read More
Lowered COVID-19 mRNA Vaccine Antibody Response in MS Patients Treated with B -Cell Depleting and S1P-Receptor-Targeting Therapies Compared to Controls: An Interim Analysis
Background: There are two mRNA vaccines targeting the SARS-CoV2 virus widely used in the U.S. There is limited knowledge about SARS-CoV2 mRNA vaccine response in...
Read More
Multiple Sclerosis Diagnosis: Challenges in Telehealth
Background: The COVID-19 pandemic ushered in a new era of telehealth to decrease transmission of the SARS-CoV-2 virus. While this increased access to care for...
Read More
Patient Practices and Experiences during COVID-19 Among Individuals across the United States Enrolled in MS Lifelines Patient Support Program
Background: Research into the impact of COVID-19 on people with MS is ongoing. Objectives: To gain an understanding of COVID-19 practices and experiences among patients...
Read More
Patient-Centered Education and Care Coordination Initiative to Improve Self-Management Skills in Latinos with Multiple Sclerosis
Background: Multiple sclerosis (MS) is a chronic, disabling neurological disease that attacks young adults. Similar to many other chronic conditions in patients with MS, self-management...
Read More
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab
Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in adults. As per the ofatumumab label,...
Read More
Primary Results of NOVA: A Randomized Controlled Study of the Efficacy of 6 Week Dosing of Natalizumab Versus Continued 4-Week Treatment
Background: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing frequency of approximately 6 weeks (Q6W) is associated...
Read More
Sustained B-Cell Depletion By Inebilizumab Is Associated with Decreased Disease Activity in Aquaporin-4 Seropositive Neuromyelitis Optica Spectrum Disorder
Background: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to treat neuromyelitis optica spectrum disorder (NMOSD) in...
Read More
Temporal Trends in Humoral and Cellular Immune Responses to Sars-Cov-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated with Natalizumab, Ocrelizumab or Fumarates
Background: Vaccines against SARS-CoV-2 are a key component of public health measures to combat the COVID-19 pandemic. The impact of immunomodulatory therapies on the efficacy...
Read More
The Humoral Response to Sars-COV-2 Vaccines in MS Patients: Impact of Dmt, Lymphocyte Count, Immunoglobulins, and Vaccine Type
Background: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic, and immunological variables can potentially impact vaccine response...
Read More
US Real World Experience Switching from Infusion and S1P Therapies to Cladribine Tablets: A Single Center Study
Background: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets received approval in the United...
Read More
Variables Affecting Disease Modifying Therapy Adherence and Impact of Adherence on Multiple Sclerosis Patients (Egyptian experience)
Background: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more prone to disability progression affecting their physical...
Read More